Thursday, November 5, 2026
ExploreSearch
Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· June 8, 2026

Mixed or Offshore Upstream E&P Stocks Q1 Recap: Benchmarking SM Energy (NYSE:SM)

View original at finance.yahoo.com
Mixed or Offshore Upstream E&P Stocks Q1 Recap: Benchmarking SM Energy (NYSE:SM) Looking back on mixed or offshore upstream e&p stocks’ Q1 earnings, we examine this quarter’s best and worst performers, including SM Energy (NYSE:SM) and its peers…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • On average, shares of the 21 tracked mixed or offshore upstream E&P companies are down 6.8% since the latest earnings results.

    60% confidence

  • SM is off to an outstanding start in 2026.

    60% confidence

  • Smaller or niche E&P companies face headwinds including higher operational and geological risks, limited scale, constrained capital market access, and disproportionate regulatory and ESG risks.

    60% confidence

  • As a group, the 21 mixed or offshore upstream E&P stocks reported Q1 revenues that missed analysts' consensus estimates by 5%.

    60% confidence

  • SM Energy Q1 2026 revenues of $1.48 billion exceeded analysts' expectations by 5.8%, with beats also on EPS and EBITDA estimates.

    60% confidence

  • Seadrill Q1 2026 revenues of $358 million outperformed analysts' expectations by 7.2%, with beats also on EPS and EBITDA estimates.

    60% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Oncology Data Season and Biotech Capital Allocation: ESMO Readouts, Ivonescimab PDUFA, and Diverging Corporate Moves
Late-2026 biotech is driven by a dense catalyst calendar. ESMO 2026 delivers data from ivonescimab, Enhertu, R-DXd and bemarituzumab, and the FDA has set a 14 Nov PDUFA date for the ivonescimab BLA. Capital allocation is diverging. Krystal Biotech authorized a $400M buyback while lowering FY2026 spend guidance and pushing milestones into 2027. Spago is moving to delist from Nasdaq First North. The facts are clinical and corporate events, not AI or fintech, so the finance angle is limited to capital markets (buybacks, guidance, delistings, regulatory timelines).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,549 source documents archived
Query this data → isubstrate.com